Raptor’s mission is to research, produce, and deliver medicines that improve life for patients with severe, rare diseases.

 

RAPTOR'S PHASE 3 CLINICAL TRIAL MEETS PRIMARY ENDPOINT

Raptor’s Phase 3 clinical trial of Delayed-Release or DR Cysteamine, known as study drug RP103, for the treatment of nephropathic cystinosis, met the primary endpoint of non-inferiority compared to currently marketed immediate-release cysteamine bitartrate.